Summary of Product Characteristics Patient Leaflet Safety Information AAA | Print

US RESIDENTS | This site is intended for healthcare professionals outside the US.

References: 1. Signifor Summary of Product Characteristics. Novartis Pharma AG. 2. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914-924.
Disclaimer: This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country specific and may contain information that is outside the approved indications in the country in which you are located.

About Novartis Oncology Contact Us Site Map Use of Web site is governed by the Terms of Use and Privacy Policy
© Novartis AG

Theme Template for Bootstrap